Reportlinker Adds Colorectal Cancer Drug Futures

Oct 19, 2010, 13:27 ET from Reportlinker

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Colorectal Cancer Drug Futures

http://www.reportlinker.com/p0315765/Colorectal-Cancer-Drug-Futures.html

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Colorectal Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.

24/7 web access

Quarterly updated pdf reports

Single cost-effective price

All updates including any new drugs added during your license period

Related news

Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Early-stage colorectal cancer (CRC) is generally treated with surgery and radiation....

....with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found at this early stage, and, as a result, there remains considerable unmet clinical need within the CRC market.

For those patients who experience recurrence following surgery there is a clear need for effective therapies earlier in the course of the disease. In addition, with around 76% of patients (Stages II-IV) eligible for chemotherapy, new formulations which improve patients' quality of life and increase survival are sorely needed.

In 2008, the CRC drug market (US, EU and Japan) for major branded therapies was valued at just over US$8 billion. Whilst chemotherapy is the mainstay of CRC treatment the use of targeted therapies are gaining acceptance in the treatment of advanced disease. This trend is expected to continue as new combinations are evaluated and therapies are increasingly used in the adjuvant setting to address the unmet clinical needs within the market. Indeed, by 2015 targeted therapies will account for 77% of the CRC market.

Which products and companies will benefit from this trend?

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Colorectal Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug's progress and stay abreast of developments

Understand the drug's novelty and mode of action

Evaluate the strength of the company developing/producing the drug

Review opportunities and challenges with Espicom's unique 5-point competitive assessment

Know the launch timeframe for new products or indications

Be aware of promising mid-stage development candidates

Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates

Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action

Current status

Proof of concept/clinical data

Development risks

Company expertise

Competition within the market-place

Sales forecast (for key late-stage and launched products)

Competitor ratio analysis score

Clinical trial results

50 CRC ACTIVE DRUGS INCLUDE:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved

Bevacizumab

Capecitabine

Cetuximab

Doxifluridine

Irinotecan

Oxaliplatin

Panitumumab

Phase III

Aflibercept

Brivanib

Cediranib

HA-irinotecan

OncoVAX

Perifosine

Regorafenib

Talaporfin sodium

Phase II/III

Canfosfamide

Phase II

Adecatumumab

Angiocept

Arenegyr

AZD6244

BIBF 1120

Cixutumumab

Conatumumab

CPX-1

CS-7017

Davanat

Enzastaurin

Figitumumab

GDC-0449

Gimatecan

Linifanib

Mapatumumab

Necitumumab

Pemetrexed disodium

Picoplatin

Ramucirumab

RG 7204

SAR109659

Sorafenib

Sunitinib

TAS-102

Telatinib

Tigatuzumab

Phase I/II

ARQ 197

EMD525797

Phase I

184072

Dulanermin

IMO-2055

Interleukin-21

Pazopanib

Tivozanib

Discontinued

ABT-751

GDC-0449

PD-325901

Trastuzumab

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

Table of Contents

OVERVIEW ... 1

PHASE I... 3

184072 .. 3

Current Status ... 3

DULANERMIN .... 4

Mode of Action .. 4

Current Status ... 4

Proof of Concept ..... 4

Development Risks .. 4

Company Expertise .. 4

Competition Within the Market-place ..... 5

Competitor Ratio Analysis .... 5

Clinical Trial Results .. 5

IMO-2055 ..... 6

Mode of Action .. 6

Current Status ... 6

Proof of Concept/Clinical Data ... 6

Company Expertise .. 7

Clinical Trial Results . 7

INTERLEUKIN-21 .... 8

Mode of Action .. 8

Current Status ... 8

Proof of Concept/Clinical Data ... 9

Development Risks .. 9

Company Expertise .. 9

Competition within the Market-place ...10

Competitor Ratio Analysis ..10

Clinical Trial Results 10

PAZOPANIB 12

Mode of Action 12

Current Status .12

Proof of Concept/Clinical Data .14

Development Risks .14

Company Expertise .15

Competition within the Market-place ...15

Data Exclusivity .....16

Patent Expiry ...16

Competitor Ratio Analysis ..16

Forecast ...17

Clinical Trial Results .....18

TIVOZANIB 20

Mode of Action 20

Current Status .20

Proof of Concept/Clinical Data .20

Development Risks .21

Company Expertise .21

Competition within the Market-place ...22

Competitor Ratio Analysis ..22

Forecast ...23

PHASE I/II .. 24

ARQ 197 ..... 24

Mode of Action 24

Current Status .24

Proof of Concept/Clinical Data .24

Development Risks .25

Company Expertise .25

Competition within the Market-place ...26

Competitor Ratio Analysis ..26

Clinical Trial Results 26

EMD 525797 .... 29

Mode of Action 29

Current Status .29

PHASE II ..... 30

ADECATUMUMAB .. 30

Mode of Action 30

Current Status .30

Proof of Concept/Clinical Data .30

Development Risks .32

Company Expertise .32

Competition within the Market-place ...32

Clinical Trial Results .....33

ANGIOCEPT 35

Mode of Action 35

Current Status .35

Proof of Concept/Clinical Data .35

Development Risks .35

Company Expertise .35

Competition within the Market-place ...36

Competitor Ratio Analysis ..36

ARENEGYR . 37

Mode of Action 37

Current Status .37

Proof of Concept/Clinical Data .38

Development Risks .39

Company Expertise .39

Competition within the Market-place ...40

Competitor Ratio Analysis ..41

AZD6244.... 42

Mode of Action 42

Current Status .42

Clinical Trial Results 42

BIBF 1120 .....44

Mode of Action 44

Current Status .44

Proof of Concept/Clinical Data .45

Development Risks .45

Company Expertise .45

Competition Within the Market-place ...46

Competitor Ratio Analysis ..46

Forecast ...47

Clinical Trial Results 47

CIXUTUMUMAB ..... 49

Mode of Action 49

Current Status .49

Proof of Concept/Clinical Data .50

Development Risks .50

Company Expertise .50

Competition within the Market-place ...50

Competitor Ratio Analysis ..50

CONATUMUMAB .... 52

Mode of Action 52

Current Status .52

Proof of Concept ...52

Development Risks .52

Company Expertise .52

Competition Within the Market-place ...53

Competitor Ratio Analysis ..53

CPX-1 ... 54

Mode of Action 54

Current Status .54

Proof of Concept/Clinical Data .54

Development Risks .55

Company Expertise .55

Competition within the Market-place ...55

Competitor Ratio Analysis ..55

CS-7017 56

Mode of Action 56

Current Status .56

DAVANAT .... 57

Mode of Action 57

Current Status .57

Proof of Concept/Clinical Data .57

Development Risks .58

Company Expertise .58

Competition within the Market-place ...58

Competitor Ratio Analysis ..59

ENZASTAURIN . 60

Mode of Action 60

Current Status .60

Proof of Concept/Clinical Data .60

Development Risks .62

Company Expertise .62

Competition within the Market-place ...62

Competitor Ratio Analysis ..63

Forecast ...63

Clinical Trial Results .....64

FIGITUMUMAB 65

Mode of Action 65

Current Status .65

Proof of Concept ...65

Development Risks .66

Company Expertise .66

Competition Within the Market-place ...66

Competitor Ratio Analysis ..67

Clinical Trial Results 68

GDC-0449 ... 69

Mode of Action 69

Current Status .69

Proof of Concept/Clinical Data .69

Development Risks .70

Company Expertise .70

Competition within the Market-place ...71

Competitor Ratio Analysis ..71

Clinical Trial Results 71

GIMATECAN ..... 73

Mode of Action 73

Proof of Concept/Clinical Data .73

LINIFANIB . 74

Mode of Action 74

Current Status .74

Proof of Concept/Clinical Data .74

Development Risks .75

Company Expertise .75

Competition within the Market-place ...75

Competitor Ratio Analysis ..76

MAPATUMUMAB .... 77

Mode of Action 77

Current Status .78

Proof of Concept ...78

Development Risks .78

Company Expertise .79

Competition Within the Market-place ...79

Competitor Ratio Analysis ..79

Forecast ...79

Clinical Trial Results 79

NECITUMUMAB ..... 81

Mode of Action 81

Current Status .81

Proof of Concept/Clinical Data .81

Development Risks .81

Company Expertise .82

Competition within the Market-place ...82

Competitor Ratio Analysis ..83

PEMETREXED DISODIUM 84

Mode of Action 84

Current Status .84

Proof of Concept/Clinical Data .85

Development Risks .86

Company Expertise .86

Competition within the Market-place ...86

Data Exclusivity .....87

Patent Expiry ...87

Generic Competition .....87

Competitor Ratio Analysis ..87

Forecast ...88

Clinical Trial Results 88

Metastatic Breast Cancer ....89

PICOPLATIN .... 90

Mode of Action 90

Current Status .90

Proof of Concept/Clinical Data .90

Development Risks .91

Company Expertise .91

Competition within the Market-place ...92

Patent Expiry ...92

Competitor Ratio Analysis ..93

RAMUCIRUMAB ..... 94

Mode of Action 94

Current Status .94

Proof of Concept/Clinical Data .94

Development Risks .94

Company Expertise .95

Competition within the Market-place ...95

Competitor Ratio Analysis ..95

Forecast ...96

RG7204 . 97

Mode of Action 97

Current Status .97

Proof of Concept ...97

Clinical Trial Results 98

SAR109659 .... 100

Mode of Action ....100

Current Status .....100

Proof of Concept/Clinical Data .....100

Development Risks .....101

Company Expertise .....101

Competition within the Market-place .101

Competitor Ratio Analysis 101

Clinical Trial Results ....102

SORAFENIB .... 104

Mode of Action ....104

Current Status .....105

Proof of Concept/Clinical Data .....106

Development Risks .....107

Company Expertise .....107

Competition within the Market-place .108

Data Exclusivity ...108

Patent Expiry .109

Competitor Ratio Analysis 110

Forecast .110

Clinical Trial Results ....112

SUNITINIB MALATE . 113

Mode of Action ....113

Current Status .....114

Proof of Concept/Clinical Data .....115

Development Risks .....116

Company Expertise .....117

Competition within the Market-place .117

Data Exclusivity ...118

Patent Expiry .118

Generic Competition ...118

Competitor Ratio Analysis 118

Forecast .120

Clinical Trial Results ....122

TAS-102 .... 125

Mode of Action ....125

Current Status .....125

TELATINIB ..... 126

Current Status .....126

Proof of Concept/Clinical Data .....126

Development Risks .....126

Company Expertise .....126

Competition within the Market-place .127

Competitor Ratio Analysis 127

TIGATUZUMAB .... 128

Mode of Action ....128

Current Status .....128

PHASE II/III ... 129

CANFOSFAMIDE .. 129

Mode of Action ....129

Current Status .....129

Proof of Concept/Clinical Data .....129

Development Risks .....130

Company Expertise .....130

Competition within the Market-place .130

Competitor Ratio Analysis 132

PHASE III . 133

AFLIBERCEPT 133

Mode of Action ....133

Current Status .....133

Proof of Concept/Clinical Data .....133

Development Risks .....135

Company Expertise .....136

Competition within the Market-place .136

Competitor Ratio Analysis 137

Forecast .137

Clinical Trial Results ....139

BRIVANIB 141

Mode of Action ....141

Current Status .....141

Proof of Concept/Clinical Data .....141

Development Risks .....142

Company Expertise .....142

Competition within the Market-place .142

Competitor Ratio Analysis 144

Forecast .144

ERLOTINIB ..... 147

Mode of Action ....147

Current Status .....147

Proof of Concept/Clinical Data .....148

Development Risks .....150

Company Expertise .....151

Competition within the Market-place .151

Data Exclusivity ...152

Patent Expiry .152

Generic Competition ...153

Competitor Ratio Analysis 153

Forecast .153

Clinical Trial Results ....154

HA-IRINOTECAN . 157

Mode of Action ....157

Current Status .....157

Proof of Concept/Clinical Data .....157

Development Risks .....158

Company Expertise .....158

Competition within the Market-place .159

Competitor Ratio Analysis 159

ONCOVAX . 160

Mode of Action ....160

Current Status .....160

Proof of Concept/Clinical Data .....160

Development Risks .....161

Company Expertise .....161

Competition within the Market-place .162

Competitor Ratio Analysis 163

Forecast .164

PERIFOSINE .. 166

Mode of Action ....166

Current Status .....167

Proof of Concept/Clinical Data .....167

Development/Commercialisation Risks ....168

Company Expertise .....168

Competition within the Market-place .169

Competitor Ratio Analysis 169

Forecast .169

REGORAFENIB ..... 170

Mode of Action ....170

Current Status .....170

Proof of Concept/Clinical Data .....170

Development Risks .....171

Company Expertise .....171

Competition within the Market-place .171

Competitor Ratio Analysis 171

Clinical Trial Results ....173

TALAPORFIN SODIUM .... 174

Mode of Action ....174

Current Status .....174

Proof of Concept/Clinical Data .....174

Development Risks .....175

Company Expertise .....175

Competition within the Market-place .175

Competitor Ratio Analysis 176

Forecast .176

Clinical Trial Results ....177

LAUNCHED PRODUCTS 178

BEVACIZUMAB ..... 178

Mode of Action ....178

Current Status .....179

Proof of Concept/Clinical Data .....182

Development Risks .....186

Company Expertise .....187

Competition within the Market-place .187

Competitor Ratio Analysis 189

Forecast .189

Clinical Trial Results ...194

CAPECITABINE .... 198

Mode of Action ....198

Current Status .....198

Proof of Concept/Clinical Data .....200

Development Risks .....202

Company Expertise .....202

Competition within the Market-place .203

Patent Expiry .203

Competitor Ratio Analysis 203

Forecast .205

Clinical Trial Results ....207

CETUXIMAB ... 210

Mode of Action ....210

Current Status .....210

Proof of Concept/Clinical Data .....211

Development Risks .....213

Company Expertise .....213

Competition within the Market-place .214

Generic Competition ...215

Competitor Ratio Analysis 215

Forecast .215

Clinical Trial Results ...216

DOXIFLURIDINE . 221

Mode of Action ....221

Current Status .....221

IRINOTECAN .. 222

Mode of Action ....222

Current Status .....222

Proof of Concept/Clinical Data .....222

Development Risks .....223

Company Expertise .....223

Competition within the Market-place .223

Patent Expiry .224

Generic Competition ...224

Competitor Ratio Analysis 225

Forecast .226

OXALIPLATIN 228

Mode of Action ....228

Current Status .....228

Proof of Concept/Clinical Data .....229

Development Risks .....229

Company Expertise .....230

Competition within the Market-place .230

Patent Expiry .231

Generic Competition ...231

Competitor Ratio Analysis 232

Forecast .232

PANITUMUMAB ... 234

Mode of Action ....234

Current Status .....235

Proof of Concept/Clinical Data .....236

Development Risks .....238

Company Expertise .....238

Competition within the Market-place .239

Competitor Ratio Analysis 239

Forecast ...240

Clinical Trial Results ...241

TEGAFUR+GIMERACIL+OTERACIL 244

Mode of Action ....244

Current Status .....244

Company Expertise .....244

TEGAFUR+URACIL .... 245

Current Status .....245

Company Expertise .....245

Clinical Trial Results ...245

DEVELOPMENT DISCONTINUED ... 247

ABT-751 .... 247

Mode of Action ....247

Current Status .....247

CEDIRANIB .... 248

Current Status .....248

Proof of Concept/Clinical Data .....249

Development Risks .....249

Company Expertise .....249

Competition Within the Market-place .250

Competitor Ratio Analysis 251

Forecast .251

Clinical Trial Results ....253

PD-325901 ..... 255

Mode of Action ....255

Current Status .....255

Proof of Concept/Clinical Data .....255

TRASTUZUMAB .... 256

Mode of Action ....256

Current Status .....257

Proof of Concept/Clinical Data .....260

Development Risks .....261

Company Expertise .....262

Competition within the Market-place .262

Patent Expiry .263

Competitor Ratio Analysis 263

Forecast .264

Clinical Trial Results ....265

METHODOLOGY ... 268

To order this report:

Drug and Medication Industry: Colorectal Cancer Drug Futures

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!


Contact Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626




SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com